New study aims to sharpen prostate cancer treatment choices

This study looks at whether combining a genomic test (Oncotype DX GPS) with MRI scans can better identify men with prostate cancer who are good candidates for focal therapy—a treatment that targets only the cancerous areas, sparing healthy tissue. Researchers will analyze stored tissue samples and past MRI images from 241 men with low- or intermediate-risk prostate cancer. The goal is to see if the GPS score, together with MRI findings, can predict which men have more aggressive disease that might not be suitable for focal therapy.